Companies › Lantheus Biosciences
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Neurology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [18F]PI-2620 Tau PET imaging agent | – | Phase 3 | Alzheimer Disease; Parkinson's Disease | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07020026 | [18F]PI-2620 | Phase 2 | Parkinson's Disease | Neurology | Apr 2027 |
| NCT05641688 | [18F]PI-2620 | Phase 3 | Alzheimer Disease | Neurology | Mar 2028 |
Cash of $684m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.